Table 1 Characteristics of children enrolled in the HIV programs at the time of registration and their outcomes.
<18 months | 18–59 months | ≥ 60 months | Total | |
|---|---|---|---|---|
Number of children registered | 69 (5.9%) | 479 (41.0%) | 620 (53.1%) | 1168 |
Gender | ||||
Female | 33 (47.8%) | 230 (48.0%) | 292 (47.1%) | 555 (47.5%) |
WHO or CDC stage | ||||
WHO 1/2 or CDC stage N/A/B | 34 (50.0%) | 310 (64.7%) | 395 (63.7%) | 739 (63.3%) |
WHO 3/4 or CDC C | 34 (50.0%) (n = 68) | 169 (35.3%) | 225 (36.3%) | 428 (36.7%) (n = 1167) |
CD4 cells/mm3, median (IQR) | 753 (338–1280) (n = 40) | 643 (310–1049) (n = 353) | 245 (40–599) (n = 561) | 410 (94–818) (n = 954) |
CD4 cells/mm3 | ||||
<50 | 2 (5.0%) | 22 (6.2%) | 149 (26.6%) | 173 (18.1%) |
50–350 | 8 (20.0%) | 75 (21.3%) | 175 (31.2%) | 258 (27.0%) |
>350 | 30 (75.0%) | 256 (72.5%) | 237 (42.2%) | 523 (54.8%) |
CD4%, median (IQR) | 18.71(12.44–23.75) (n = 48) | 18 (10–24.8) (n = 415) | 9.41 (2.76–18.72) (n = 399) | 14.47 (5.33–23) (n = 862) |
CD4% group3 | ||||
<15.0% | 16 (33.3%) | 164 (39.5%) | 260 (65.2%) | 440 (51.0%) |
15–24.9% | 21 (43.7%) | 148 (35.7%) | 81 (20.3%) | 250 (29.0%) |
≥ 25.0% | 11 (22.9%) | 103 (24.8%) | 58 (14.5%) | 172 (20.0%) |
Weight for height* | ||||
≥ -2 z-score | 33 (55.0%) | 366 (81.0%) | 435 (76.7%) | 834 (77.3%) |
<-2 and ≥ -3 z-score | 12 (20.0%) | 53 (11.7%) | 82 (14.5%) | 147 (13.6%) |
<-3 z-score | 15 (25.0%) | 33 (7.3%) | 50 (8.8%) | 98 (9.1%) |
Weight for age | ||||
≥ -2 z-score | 29 (42%) | 153 (31.9%) | 127 (20.5%) | 309 (26.5%) |
<-2 and ≥ -3 z-score | 12 (17.4%) | 176 (36.7%) | 287 (46.4%) | 475 (40.7%) |
<-3 z-score | 28 (40.6%) | 150 (31%) | 205 (33.1%) | 383 (32.8%) |
Year of admission | ||||
2003 | 2 (2.9%) | 53 (11.1%) | 36 (5.8%) | 91 (7.8%) |
2004 | 13 (18.8%) | 117 (24.4%) | 183 (29.5%) | 313 (26.8%) |
2005 | 17 (24.6%) | 123 (25.7%) | 165 (26.6%) | 305 (26.1%) |
2006 | 19 (27.5%) | 109 (22.8%) | 130 (21.0%) | 258 (22.1%) |
2007 | 18 (26.1%) | 77 (16.1%) | 106 (17.1%) | 201 (17.2%) |
Started ART§ | 42 (60.9%) | 278 (58.0%) | 394 (63.6%) | 714 (61.1%) |
Follow up time in days, median (IQR) | 333 (134–840) | 755 (349–1207) | 750.5 (320.5–1193) | 733.5 (314.5–1182.5) |
Outcome on study termination: | ||||
Alive and in active follow up | 40 (58.0%) | 361 (75.4%) | 448 (72.3%) | 849 (72.7%) |
Dead | 15 (21.7%) | 37 (7.7%) | 53 (8.6%) | 105 (9.0%) |
Lost to follow up* | 8 (11.6%) | 42 (8.8%) | 63 (10.2%) | 113 (9.7%) |
transferred 6 (8.7%) | 39 (8.1%) | 56 (9.0%) | 101 (8.6%) |